The FDA’s 510(k) clearance was based in part on the company’s pivotal PRESERVE study, which reported 84% of men with no clinically significant disease after 12 months. (Photo by Sarah Silbiger/Getty ...
The VIOLETTE trial, which used OBT-fusion technology for patients with focal ablation of the prostate by microwave needles, released interim results. Investigators of the multicentric, phase 2 ...
Francis Medical's Vanquish wields water vapor to overcome some of the limitations of traditional thermal ablation by applying high pressure in 10-second bursts through a catheter. (Francis Medical) ...
MINNEAPOLIS and ATLANTA, April 16, 2026 /PRNewswire/ -- Francis Medical, Inc., a privately held medical device company, today announced the continued expansion of its U.S. commercial launch with the ...
LOS ANGELES, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Clinical Laserthermia Systems Americas, Inc. (CLS), a leading provider of office-based, focal laser ablation (FLA) systems for urologists, and HALO ...
Prostate cancer patients may soon have a new option to treat their disease: laser heat. UCLA researchers have found that focal laser ablation - the precise application of heat via laser to a tumor - ...
Francis Medical's Vanquish device for treating intermediate-risk prostate cancer has been cleared by the US Food and Drug Administration (FDA). Vanquish is a transurethral, ultrasound and ...
Minimally invasive transperineal laser ablation (TPLA) of the prostate appears effective for benign prostatic hyperplasia (BPH), according to a review published online Sept. 21 in Therapeutic Advances ...
Use of the Prostatype P-score to predict adverse pathology (AP) at radical prostatectomy (RP). This is an ASCO Meeting Abstract from the 2024 ASCO Genitourinary Cancers Symposium. This abstract does ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results